Healthcare Stocks Lag Amid War Jitters; DaVita Leads Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy DVA?
Source: seekingalpha
- Healthcare Sector Pullback: Healthcare services and providers have traded defensively over the past week due to Iran-related war jitters, with the flagship Health Care Select Sector SPDR ETF (XLV) declining approximately 4.5% over five trading days, indicating a cautious market sentiment towards risk assets.
- DaVita's Strong Position: Among large-cap healthcare stocks, DaVita Inc. (DVA) stands out with a Strong Buy rating of 4.81, making it the only stock in the list with such a rating, which highlights its relative strength in the current market environment.
- Other Stock Ratings: Following DaVita, CVS Health Corporation (CVS) and Quest Diagnostics Incorporated (DGX) hold ratings of 3.32 and 3.26 respectively, both classified as Hold, reflecting a cautious outlook that may impact their future investment appeal.
- Rating System Overview: Seeking Alpha's Quant Ratings assess stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with scores ranging from 1 to 5, where ratings above 3.5 are considered bullish and below 2.5 bearish, illustrating the mixed sentiment within the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 152.560
Low
144.00
Averages
162.50
High
190.00
Current: 152.560
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Healthcare Stocks Lag Amid War Jitters; DaVita Leads Ratings
- Healthcare Sector Pullback: Healthcare services and providers have traded defensively over the past week due to Iran-related war jitters, with the flagship Health Care Select Sector SPDR ETF (XLV) declining approximately 4.5% over five trading days, indicating a cautious market sentiment towards risk assets.
- DaVita's Strong Position: Among large-cap healthcare stocks, DaVita Inc. (DVA) stands out with a Strong Buy rating of 4.81, making it the only stock in the list with such a rating, which highlights its relative strength in the current market environment.
- Other Stock Ratings: Following DaVita, CVS Health Corporation (CVS) and Quest Diagnostics Incorporated (DGX) hold ratings of 3.32 and 3.26 respectively, both classified as Hold, reflecting a cautious outlook that may impact their future investment appeal.
- Rating System Overview: Seeking Alpha's Quant Ratings assess stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with scores ranging from 1 to 5, where ratings above 3.5 are considered bullish and below 2.5 bearish, illustrating the mixed sentiment within the healthcare sector.
See More
Analysis of Buffett's Investment Portfolio
- American Express Opportunity: With a market cap exceeding $47 billion, American Express is facing pressures from economic slowdowns affecting consumer spending; however, its affluent clientele's luxury spending grew 15% year-over-year in Q4, indicating resilience and potential buying opportunities for investors.
- Constellation Brands Outlook: Despite a decline in share price since late 2024 and a drop in U.S. alcohol consumption to a multi-decade low of 54%, Constellation is undergoing a self-reform by divesting lower-priced wine brands, and the new CEO is expected to bring fresh perspectives for future growth.
- DaVita Investment Risks: DaVita's revenue growth is modest at 5%, while net income has decreased by 17%, highlighting broader challenges in the healthcare sector; Buffett's gradual exit from this holding signals concerns about its future performance, warranting caution from investors.
- Market Environment Impact: U.S. household debt has reached a record $18.8 trillion, with delinquency rates nearing a decade high of 4.8%, posing pressures on credit companies like American Express, making it crucial for investors to monitor macroeconomic influences on consumer credit.
See More
Rising U.S. Household Debt Impacts Credit Markets
- Rising Delinquencies: U.S. household debt has reached a record $18.8 trillion, with delinquency rates nearing a decade high of 4.8%, putting pressure on lenders like American Express and potentially impacting their future profitability.
- American Express Resilience: Despite economic headwinds, American Express saw luxury spending grow 15% year-over-year in Q4, indicating resilience among affluent customers, which may provide support for its stock price amidst broader market concerns.
- Cyclical Challenges in Brewing: Constellation Brands has underperformed since 2024, with shares declining as the proportion of U.S. adults consuming alcohol falls to 54%, yet the cyclical nature of the industry suggests demand may rebound when consumer confidence improves.
- Healthcare Sector Struggles: DaVita's revenue growth is only 5% while net income has dropped 17%, highlighting broader challenges in the healthcare industry, prompting Berkshire Hathaway to begin scaling back its investment in the company, reflecting concerns over its future outlook.
See More
Berkshire Hathaway's Performance in Buffett's Last Quarter
Warren Buffett's Departure: Warren Buffett stepped down as CEO of Berkshire Hathaway, marking the end of an era after over 60 years, with Greg Abel taking over leadership as the company reported its final earnings under Buffett's direction.
Financial Performance: Berkshire Hathaway's earnings fell significantly in 2025, with a nearly 25% drop in insurance investment income and a 6% decline in operating profit, despite a record cash reserve of $373.3 billion.
Stock Holdings and Acquisitions: Buffett's final moves included maintaining a strong portfolio with major holdings in Apple, American Express, and Bank of America, while also expanding positions in energy and media sectors.
Market Trends and Recommendations: Analysts are recommending five specific stocks for investors to consider, highlighting their potential for growth amidst broader market challenges, with a focus on sectors like energy and materials.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Healthcare Stocks Lag Amid War Jitters; DaVita Leads Ratings
- Healthcare Sector Pullback: Healthcare services and providers have traded defensively over the past week due to Iran-related war jitters, with the flagship Health Care Select Sector SPDR ETF (XLV) declining approximately 4.5% over five trading days, indicating a cautious market sentiment towards risk assets.
- DaVita's Strong Position: Among large-cap healthcare stocks, DaVita Inc. (DVA) stands out with a Strong Buy rating of 4.81, making it the only stock in the list with such a rating, which highlights its relative strength in the current market environment.
- Other Stock Ratings: Following DaVita, CVS Health Corporation (CVS) and Quest Diagnostics Incorporated (DGX) hold ratings of 3.32 and 3.26 respectively, both classified as Hold, reflecting a cautious outlook that may impact their future investment appeal.
- Rating System Overview: Seeking Alpha's Quant Ratings assess stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with scores ranging from 1 to 5, where ratings above 3.5 are considered bullish and below 2.5 bearish, illustrating the mixed sentiment within the healthcare sector.
See More
Analysis of Buffett's Investment Portfolio
- American Express Opportunity: With a market cap exceeding $47 billion, American Express is facing pressures from economic slowdowns affecting consumer spending; however, its affluent clientele's luxury spending grew 15% year-over-year in Q4, indicating resilience and potential buying opportunities for investors.
- Constellation Brands Outlook: Despite a decline in share price since late 2024 and a drop in U.S. alcohol consumption to a multi-decade low of 54%, Constellation is undergoing a self-reform by divesting lower-priced wine brands, and the new CEO is expected to bring fresh perspectives for future growth.
- DaVita Investment Risks: DaVita's revenue growth is modest at 5%, while net income has decreased by 17%, highlighting broader challenges in the healthcare sector; Buffett's gradual exit from this holding signals concerns about its future performance, warranting caution from investors.
- Market Environment Impact: U.S. household debt has reached a record $18.8 trillion, with delinquency rates nearing a decade high of 4.8%, posing pressures on credit companies like American Express, making it crucial for investors to monitor macroeconomic influences on consumer credit.
See More
Rising U.S. Household Debt Impacts Credit Markets
- Rising Delinquencies: U.S. household debt has reached a record $18.8 trillion, with delinquency rates nearing a decade high of 4.8%, putting pressure on lenders like American Express and potentially impacting their future profitability.
- American Express Resilience: Despite economic headwinds, American Express saw luxury spending grow 15% year-over-year in Q4, indicating resilience among affluent customers, which may provide support for its stock price amidst broader market concerns.
- Cyclical Challenges in Brewing: Constellation Brands has underperformed since 2024, with shares declining as the proportion of U.S. adults consuming alcohol falls to 54%, yet the cyclical nature of the industry suggests demand may rebound when consumer confidence improves.
- Healthcare Sector Struggles: DaVita's revenue growth is only 5% while net income has dropped 17%, highlighting broader challenges in the healthcare industry, prompting Berkshire Hathaway to begin scaling back its investment in the company, reflecting concerns over its future outlook.
See More
Berkshire Hathaway's Performance in Buffett's Last Quarter
Warren Buffett's Departure: Warren Buffett stepped down as CEO of Berkshire Hathaway, marking the end of an era after over 60 years, with Greg Abel taking over leadership as the company reported its final earnings under Buffett's direction.
Financial Performance: Berkshire Hathaway's earnings fell significantly in 2025, with a nearly 25% drop in insurance investment income and a 6% decline in operating profit, despite a record cash reserve of $373.3 billion.
Stock Holdings and Acquisitions: Buffett's final moves included maintaining a strong portfolio with major holdings in Apple, American Express, and Bank of America, while also expanding positions in energy and media sectors.
Market Trends and Recommendations: Analysts are recommending five specific stocks for investors to consider, highlighting their potential for growth amidst broader market challenges, with a focus on sectors like energy and materials.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
